We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cizzle Biotechnology Holdings Plc | LSE:CIZ | London | Ordinary Share | GB00BNG2VN02 | ORD 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.65 | 1.60 | 1.70 | 1.65 | 1.65 | 1.65 | 835,873 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 0 | -1.72M | -0.0047 | -3.51 | 6M |
From Jun 2023 to Jun 2024
TIDMCIZ
RNS Number : 6769B
Cizzle Biotechnology Holdings PLC
05 June 2023
5 June 2023
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology", "Cizzle" or the "Company")
Posting of Annual Report and Notice of AGM
Cizzle Biotechnology, the UK-based diagnostics developer, is pleased to announce that copies of the annual report and accounts for the year ended 31 December 2022, together with the notice of Annual General Meeting ("AGM"), have been sent to shareholders and are available for viewing on the Company's website at https://cizzlebiotechnology.com .
The AGM of Cizzle Biotechnology will be held at 11.00 a.m. BST on 28 June 2023 at the offices of Shakespeare Martineau LLP, 6(th) Floor, 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
Cizzle Biotechnology Holdings Via IFC Advisory plc Allan Syms (Executive Chairman) Allenby Capital Limited +44(0) 20 33285656 John Depasquale Alex Brearley Novum Securities Limited +44(0) 20 7399 9400 Colin Rowbury Jon Bellis IFC Advisory Limited +44(0) 20 3934 6630 Tim Metcalfe cizzle@investor-focus.co.uk Florence Chandler
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see https://cizzlebiotechnology.com You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOANKPBNDBKDPAK
(END) Dow Jones Newswires
June 05, 2023 07:35 ET (11:35 GMT)
1 Year Cizzle Biotechnology Chart |
1 Month Cizzle Biotechnology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
